The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.

El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...